New drug aims to ease harsh chemo side effects for breast cancer patients
NCT ID NCT06513364
Summary
This early-stage study tested a new chemotherapy drug called WH002 against a standard drug (paclitaxel) for women with HER2-negative breast cancer. The goal was to see if WH002, given before surgery along with other drugs, was safer or worked better at shrinking tumors. The trial involved 40 women and primarily looked at side effects and how the body processes the drug.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
Conditions
Explore the condition pages connected to this study.